Although SGLT2i or GLP-1 RA are preferred over other antidiabetic medications for their organ protection effect in patients with T2DM (26), we still observed a low rate of prescribing SGLT2i or GLP-1 RA in patients with T2DM and established ASCVD, HF, CKD, or obesity who were likely to benefit from these medications. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.